QuidelOrtho (QDEL) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
QuidelOrtho is the larger company by market cap ($570.9 million vs $5.1 million), about 112.5 times the size, while Trinity Biotech is growing revenue faster (+8.3% vs -1.9%). QuidelOrtho converts more of its revenue into profit, with a net margin of -41.5% versus -51.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QDEL | TRIB |
|---|---|---|
| Share price | $8.32 | $6.24 |
| Market cap | $570.86M | $5.07M |
| 1-day change | -6.73% | +13.76% |
| YTD return | -70.87% | — |
| 1-year return | -65.83% | — |
| 5-year return | -94.25% | — |
| Forward P/E | 6.32 | — |
| EPS (TTM) | $-5.39 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.73B | $61.55M |
| Revenue growth (YoY) | -1.89% | +8.31% |
| Net income (latest FY) | $-1.13B | $-31.79M |
| Gross margin | 46.67% | 34.83% |
| Operating margin | -33.67% | -34.38% |
| Net margin | -41.45% | -51.64% |
| 52-week high | $35.58 | $52.50 |
| 52-week low | $8.06 | $4.54 |
| Distance from 52-week high | -76.62% | -88.11% |
| Analyst consensus | hold | — |
| Avg. price target upside | +80.29% | — |
| Average volume | 2.04M | 13.54K |
| Shares outstanding | 68.61M | 813.13K |
| Employees | 6,500 | 287 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QuidelOrtho is about 112.5 times larger than Trinity Biotech by market value ($570.86M vs $5.07M).
- QuidelOrtho is more profitable, keeping -41.5 cents of every revenue dollar as net income versus -51.6 cents for Trinity Biotech.
- Trinity Biotech grew revenue faster in its latest fiscal year (+8.31% vs -1.89%).
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees
QDEL vs TRIB FAQ
Which is bigger, QuidelOrtho or Trinity Biotech?
QuidelOrtho (QDEL) is larger, with a market capitalization of $570.86M compared with $5.07M for Trinity Biotech (TRIB).
Are QuidelOrtho and Trinity Biotech in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.